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INTRODUCTION 
 
Tumor cells, often characterized by altered 
expression of proteins and their glycosylation patterns, 
induce humoral and cellular immune responses in the 
autologous host [1-6]. Circulating antibodies against 
tumor-associated antigens (TAAs) are a strong 
indicator of cancer and, due to a long half-life and high 
concentration in the blood, are easier to detect than the 
proteins they recognize. TAAs have usually been 
identified by using cancer patients’ serum antibodies to 
screen cDNA libraries derived from autologous or 
heterologous tumors. However, screening cDNA 
libraries, besides being laborious and time consuming, 
fails to identify TAAs generated by aberrant 
glycosylation of cell membrane glycoproteins and 
glycolipids [7]. 
An alternative to using cDNA expression libraries 
for TAA identification is to screen Random Peptide 
Phage Display Libraries (RPPDLs) with serum 
antibodies from cancer patients. RPPDLs have been 
widely utilized to map protein interaction sites. Peptide 
libraries were first used for the assessment of antibody 
specificity [8]. In this assay, a RPPDL is incubated 
with a target antibody. Subsequently, phage bound to 
the antibody are eluted and amplified in host bacteria. 
This process, termed “biopanning,” can be repeated 
several times in order to obtain an enriched population 
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serum antibodies.   
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of the best binders. Bound peptides are identified upon 
phage DNA sequencing. The amino acid sequences of 
the peptides binding to cancer-specific serum 
antibodies can mimic sequential and conformational 
epitopes of protein antigens [9] as well as carbohydrate 
epitopes of glycoproteins or glycolipids. The only 
drawback of RPPDL screening on serum antibodies is 
the lack of immediate information on the identities of 
the real antigens that are mimicked by the antibody-
binding peptides. Meanwhile, establishing these 
identities is important for the design of personalized 
immunoassay tests for reliable and specific detection of 
cancer recurrency  
  It has been demonstrated that the identity of the 
antigens mimicked by peptides obtained from RPPDL 
screening can be determined using a proteomic 
approach [10]. RPPDL screening on serum antibodies 
from a prostate cancer patient identified a peptide motif 
associated with serum antibody reactivity that 
positively correlated with progression of prostate 
cancer. A glucose-regulated protein (GRP78), a 
member of the heat-shock protein family, recognized 
by antiserum raised against the selected peptide was 
identified through a series of biochemical approaches, 
including electrophoretic fractionation and mass 
spectrometry analysis. The peptide 
recognized by the prostate cancer patient’s 
antibodies appeared to mimic a 
conformational epitope within the GRP78 
protein. The large volume of work 
required for identifying TAAs based on 
peptides mimicking conformational 
epitopes diminishes the efficiency of 
RPPDL screening for development of 
personalized immunoassay tests. Our 
work demonstrates that for peptides that 
mimic sequential epitopes, the 
corresponding TAAs can be easily 
identified by protein database homology 
searches using the basic local alignment 
search tool (BLAST). 
 
 
RESULTS 
 
Biopanning of peptide libraries on 
antibodies from colorectal cancer 
patient sera 
 
To identify peptide sequences 
recognized by cancer-specific serum 
antibodies, we used a mixture of several peptide 
libraries of variable peptide length for screening on 
IgG antibodies from the serum samples of seven 
colorectal cancer (CRC) patients. Four cycles of 
selection/amplification were performed on each serum 
sample to achieve enrichment in antibody-binding 
phage. Each cycle consisted of an initial step of library 
preadsorption on normal immunoglobulins, followed 
by an affinity selection on antibodies from the cancer 
patient serum and amplification of the phage particles 
thus selected in bacteria, as described [10]. Serum 
samples from four CRC patients, hereafter referred to 
as patients A, B, C, and D, were enrichment-positive, 
implying recovery of phage particles reacting with 
cancer-specific antibodies; sera pooled from 24 healthy 
donors served as the negative control.  Two sera 
positive for enrichment on IgG antibodies were also 
tested for enrichment on IgM antibodies. Each serum 
gave rise to phage enrichment, as the phage bound the 
corresponding IgM antibodies but not the IgM 
antibodies present in the control. Figure 1 shows the 
enrichment of phage particles that specifically bind to 
IgG antibodies from a CRC patient serum after four 
rounds of successful selection. We also performed 
library biopanning with sera obtained from four healthy 
Fig. 1 Enrichment of RPPD library with phage particles that bind specifically to 
IgG antibodies from the serum of CRC patient A after four rounds of 
biopanning. After each round of pre-adsorption on an excess of normal serum 
IgG and affinity selection on patient A IgG, amplified phage particles were 
purified and quantified. Equal amounts of phage (107 cfu) were incubated for 1 
hour with normal serum IgG and cancer patient A IgG immobilized on protein G 
agarose. After washing out unbound phage, the remaining phage were eluted 
and used to infect bacteria. Aliquots of infected bacteria were spread on LB 
plates containing tetracycline. The next day, the number of colonies on plates 
corresponding to normal IgG and cancer patient A's IgG were quantified.  
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Table 1 Peptide sequences selected from RPPDLs and the corresponding matching over-represented proteins 
Patient  Ab 
type  Peptide sequences from “biopanning” selected phages  Overrepresented proteins identified 
by BLAST search 
A  IgG  TGVRGQRISQ(9)         QNPGETSKMN(6)
a        KYRWYK(3)
a 
aNP_055982.2
 bifunctional arginine 
demethylase and lysyl-hydroxylase 
JMJD6 (2) 
  
A 
  
IgM 
AVHFPD  
DLITPGD (2) 
AEPPFEF (2) 
PSKAAYVV
a (3) 
QDLYSSA (3) 
QDIFSSA (3) 
MSSVMTY
a 
FQSPK
b(2) 
ASHQNRP  
FRQAAS 
aNP_078966.2 Mucin 16 (2) 
bNP_002025.2 Fucosyltransferase 5 
bNP_000140.1 Fucosyltransferase 3 
bNP_000141.1 Fucosyltransferase 6 
  
B 
  
IgG 
FSRRAQQVGAK(3) 
DHNRSM 
SHNRVSN 
KKGMGHHGNG 
KAYGHHLSAE(2) 
GLGVGHK 
SYSGYWHSWI 
FGAKSHGHHR 
KSNKCF 
MKQSGHHRSE 
WTRRPYDELIV  
 
C IgG 
KENGRSPTHS(10) 
GRSNKSG 
SPTHP(5)  GRRNKSG    
  
  
D 
  
  
IgG 
VPWSKPWWTQ 
GHNNHNRHHP
a 
SNVRSFDNPI 
ANTPWSKTL (2) 
IPLPPPSRPF
 b (2) 
HNTRNWTLPP(1) 
SNVISYPDV 
GNPWSKQINI 
VNTTSYNMRP(2) 
LPWSKLSSPS 
SNVKNYMAIP 
QLHPHNLHSP 
TLHTTHSPFK
a 
NYEPVPRGAR
d 
TDAAPWSKVT(2) 
GKSLHGSHHP 
SNVISFRHAS 
TNVISYTPLY(3)
a 
aNP_078966.2 Mucin 16 (2) 
  
bNP_002025.2 Fucosyltransferase 5 
  
dNP_002024.1 Fucosyltransferase 4 
  
  
  
  
D 
  
  
  
  
  
IgM 
QSLDHSSC
a (5) 
LNPQSPRD
 (4) 
YSWRAT(4) 
NERSEAR
a 
HFHHLAVRGR 
PQGWLGW 
GTVEPD 
PTRWGARLVK 
GGRWNR(2) 
PETTDK(2) 
PGHVRGTLGR
a(2) 
YVDTLSKL 
RGQSLA
c 
AVRRPD (4) 
QRLAAGFH 
QLAETLF 
GRKTELF
b 
YLASPFE
c 
FRVARAA 
RTGRMWR 
LVYPQQ 
VVGLVP
c(2) 
QIQLSGG
c 
VKNRGR 
aNP_001122080.1 mitogen-activated 
protein  kinase binding protein 1 (3) 
  
bNP_078966.2 Mucin 16 (2) 
  
cNP_001156729.1 plexin B3 (4) 
  
Normal 
control  IgG 
DIRLSAQL 
SWSGYYTY 
TNGVHHGR 
GLYNFMGK 
RRTDYLLNG 
DPTVSESS
a 
APQGYLFK 
ESSTKSE 
NQHLILSVG 
SIAAAVH 
RANKEPAT 
aNP_078966.2 Mucin 16 
All database-retrieved proteins presented in the table are of Homo sapiens origin. 
1.  Numbers in parentheses after the peptide sequences indicate the number of identical copies of the same phage identified after 
selection and sequencing. 
2.  Numbers in parenthses after the protein names indicate the number of times the protein was retrieved by BLAST homology 
search on different peptide sequences. 
3.  Highlighted in bold are conserved motifs present in different phage. 
4.  Superscript letters relate peptide sequences with the proteins retrieved by BLAST. Accession numbers provided correspond to 
the NCBI entry references. 
donors. No phage enrichment was observed as 
compared to the control serum. 
For each positive serum, the enriched phage 
population typically contained several phage groups 
with identical inserts. Some groups included sequences 
that were different but contained overlapping 
fragments (motifs), usually four or five amino acids in 
length. Several singularly represented inserts were also 
recovered. The peptide sequences derived from phage 
binding to IgG antibodies were different from those 
binding to IgM antibodies, from the same serum. Table 
1 shows the sequences of peptides identified for each 
positive serum. We also sequenced 11 inserts from 
phage isolated after one round of biopanning with IgG 
from a healthy individual. All sequences were 
different. 
 
Antibodies against the selected peptides can be 
detected in cancer patient sera by ELISA 
 
The multiple cycles of target binding and 
amplification of the bound phage in bacteria make 
RPPDL biopanning a sensitive assay capable of 
detecting very low-affinity interactions, which can be 
otherwise undetectable by standard immunoassay tests, 
such as an enzyme-linked immunosorbent assay  
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(ELISA). To evaluate the suitability of the peptides 
selected from RPPDL screening for developing a 
simple personalized immunoassay test, we cloned the 
cDNAs encoding two peptides, TGVRGQRISQ 
(patient A) and MKQSGHHRSE (patient B), in a 
glutathione S-transferase (GST) fusion vector. We 
purified the proteins expressed in bacteria in order to 
screen the cancer patients’ and healthy donors’ sera by 
ELISA. Patient A’s peptide was present in nine of the 
18 phage particles isolated after selection on his own 
IgG. Likewise, patient B’s peptide was selected on IgG 
antibodies. This peptide had a KXXGHH motif, which 
was found in five of the 14 phage particles isolated. 
Two randomly chosen peptides from unselected 
libraries were also expressed as GST fusions to be used 
as controls for non-specific binding. As seen in Figure 
2, the GST-fused peptides isolated from phage libraries 
by affinity selection on cancer sera bind IgG antibodies 
from their corresponding cancer sera in the ELISA. 
 
Protein database searching using BLAST can 
identify proteins represented by selected peptides 
 
The phage-displayed peptides bound by antibodies 
in the sera of cancer patients can represent sequential 
or conformational epitopes of protein antigens as well 
as peptide mimics of carbohydrate antigens. Assuming 
that among 70 peptide sequences identified by RPPDL 
biopanning on serum antibodies there were those 
representing sequential epitopes, we performed 
BLAST searching of the human reference protein 
database (refseq_ protein) for proteins containing 
sequence fragments identical or nearly identical to the 
sequences of the identified peptides. Since the lengths 
of serum antibody-recognized motifs were usually 
between four and six amino acids, a large number of 
proteins can produce the exact match to peptide 
sequences of such a short length solely by chance. 
Indeed, for each peptide sequence, BLAST homology 
searches using parameters adjusted to a short input 
sequence usually retrieved an average of 120 proteins. 
Supplementary tables S1-S7 show the lists of proteins 
detected by BLAST searching for each peptide. Some 
proteins were overrepresented. Generally, the most 
overrepresented proteins had the largest size. For 
example, mucin 16 (also known as CA125 ovarian 
cancer antigen) and nesprin-1 (14,507 and 8,749 amino 
acids, respectively) produced matches to 7 and 5 
peptides, respectively. Multiple matches of phage 
insert sequences to such large proteins can be 
explained by recognition by antibodies with different 
specificities and/or by a higher probability of matches 
produced by pure chance. To estimate the probability 
of a peptide-protein match being produced by chance, 
we performed a BLAST search for 70 cancer sera-
specific phage insert sequences in reverse orientation 
(i.e. “spelt backwards”) and calculated the length-
normalized match frequency for the most 
overrepresented proteins, which produced four or more 
matches to different peptides. Given that the 
probability of a match being produced by chance is 
directly proportional to the length of the protein, we 
Fig. 2 ELISA assay for binding of serum IgG antibodies to peptides isolated from RPPD libraries. Purified GST-
peptide fusion antigens were used to coat ELISA microplates. After blocking with 3% BSA in PBS the antigens 
were incubated overnight with cancer patient and normal individual sera diluted 1:200 with 3% BSA in PBS. The 
binding was detected using goat anti-human IgG antibodies conjugated with alkaline phosphatase and p-NPP as a 
substrate. GST-A and GST-B are TGVRGQRISQ and MKQSGHHRSE peptides expressed as GST-fusion 
proteins. As control peptides we used arbitrarily chosen peptides isolated from phage libraries and expressed as 
GST-fusion proteins. The average of three measurements is shown. 
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estimated that the frequency of a match by chance to a 
protein of 1,000 amino acids is f = 0.02 ± 0.01. This 
estimate indicates that the seven and five matches to 
mucin and nesprin-1, respectively, detected among 70 
phage inserts analyzed were due to chance rather than 
to recognition by antibodies with different specificities. 
However, based on this estimate, the probability of the 
403-amino acid bifunctional arginine demethylase and 
lysyl-hydroxylase 6 (JMJD6; accession number 
NP_055982.2) to produce matches by chance to two 
out of three peptides corresponding to IgG antibodies 
of patient A is p < 0.001. Since no peptide sequence 
corresponding to antibodies from other cancer patients 
or from a healthy control produced any matches to the 
JMJD6 protein, the p-value calculated by Fisher’s 
exact test is p = 0.0009, suggesting that the two 
peptides mimic real sequential epitopes of the protein. 
The 813-amino acid protein glycogen 
phosphorylase (liver form isoform 2; accession number 
NP_001157412.1) produced matches to five different 
peptides obtained on the IgG antibodies of patient D. 
However, all the peptides contained the common 
PWSK motif, which produced the match to the protein, 
thus negating the significance of the fact that the 
matches were multiple. The protein plexin B3 
(accession number NP_001156729.1) produced 
matches to four out of 24 peptides corresponding to the 
IgM antibodies of patient D. All peptide sequences 
were different, without any common motifs. No other 
peptide corresponding to other cancer patients or 
healthy donor antibodies produced a match to this 
protein, thus producing a p-value of 0.006 by Fisher’s 
exact test.   
The FUT6 and FUT4 proteins (359 and 530 
amino acids, respectively) of the fucosyltransferase 
protein family produced matches to two peptides 
corresponding to IgG antibodies of patient D. FUT6 
also produced a match to a peptide obtained on IgM 
antibodies of patient A. FUT3 and FUT5 are highly 
homologous to FUT6 and, therefore, also produced the 
identical match to the peptide. An elevated level of 
serum fucosyltransferase activity involved in the 
synthesis of Lewis histo-blood group system antigens 
is known to be associated with colorectal and other 
cancers [11-13].  Since the total tumor RNA was 
available for patient A, we analyzed the FUT6 mRNA 
level in patient A’s tumor and in other colon tumor and 
normal tissue samples.  An RT-PCR analysis showed 
that FUT6 mRNA was over-expressed only in patent’s 
A tumor but not in any other of the 13 colon tumor and 
normal tissues (Figure 3).   
 
 
DISCUSSION 
 
We have demonstrated that patient-specific 
peptides recognized by serum IgG or IgM antibodies 
can be identified using RPPD libraries. For some of the 
peptides representing sequential epitopes, the 
corresponding proteins can be identified using BLAST 
homology searches and statistical analysis.  Multiple 
matches to different peptide sequences corresponding 
to antibodies from the same cancer patient strongly 
indicate the presence of an immune response against 
the protein retrieved by BLAST.  
One problem in using serum antibodies and 
RPPDL biopanning for developing personalized 
immunoassay tests is to distinguish the peptides 
associated with tumor growth from those representing 
the patient’s immune response to other agents unrelated 
to cancer. For the peptides mimicking the sequential 
epitopes the proteins that likely induced a tumor-
associated antibody response can be identified by 
performing gene expression analysis, if the RNA from 
the patient’s tumor is available. The proteins 
overrepresented in the BLAST homology search, 
Fig. 3 Simultaneous RT-PCR amplification of FUT6 and G3PDH gene fragments from normal colon tissue and 
colon tumor tissue mRNA.  PCR products were electrophoresed on a 1% agarose gel. Numbers 1, 3, 5, 7, 9 and 
11 are RT-PCR products from normal colon samples mRNA. Numbers 2, 4, 6, 8, 10 and 12 are RT-PCR 
products from corresponding colon tumor samples. Number 13 is the PCR product obtained from a cDNA of 
normal colon obtained from Clontech. Number 14 is the RT-PCR product obtained from the tumor of colon 
cancer patient A.  
  
www.impactjournals.com/oncotarget       153                             Oncotarget 2010; 1: 148-155 
whose gene expression is up-regulated at the mRNA 
level in the tumor, are likely to represent personalized 
tumor-associated antigens produced by protein over-
expression. By combining two high-throughput 
technologies, combinatorial peptide library biopanning 
on serum IgG or IgM antibodies and microarray-based 
gene expression analysis, the peptides representing 
sequential epitopes of the subset of tumor-associated 
antigens for a cancer patient can be easily and quickly 
identified. We demonstrated that the RPPDL 
biopanning-derived peptides can be used in a simple 
ELISA test for detecting serum antibody reactivities.  
Due to the short lifespan of the IgM-producing 
plasma cells, the peptides selected by biopanning on 
serum IgM antibodies should be advantageous for 
designing an immunoassay test for detecting 
recurrences or metastases. A follow-up study using 
cancer patients’ serum samples taken at different time-
points is required to test whether the titer of IgM 
antibodies against RPPDL biopanning-selected 
peptides vanishes after surgical removal of the primary 
tumor and reappears upon tumor recurrence. 
Only four out of seven serum samples were 
positive for the enrichment of RPPDL with cancer 
patient’s antibody specific phage.  The set of selected 
peptides was unique for each cancer patient. It is 
possible that the method of selection for antibody-
binding peptides, which included an initial step of 
preadsorption of the phage libraries on normal 
immunoglobulins, prevented the identification of 
epitopes which are differentially recognized but shared 
between healthy donors and cancer patients’ 
antibodies. Antibody reactivities against such epitopes 
can be common for many cancer patients and might be 
used for developing general immunoassay tests for 
cancer detection. With the advance of next generation 
sequencing technology, it is now possible to sequence 
all the phage that bind to cancer patients and to normal 
controls’ antibodies in order to identify all possible 
differentially recognized peptides that can be used for 
designing personalized or general immunoassay tests 
for detecting recurrences or metastases. 
 
 
MATERIALS AND METHODS 
 
Cancer patient sera 
 
The study was approved by the Institutional 
Review Board.  All patients provided written informed 
consent, as required by the Institutional Review Board 
and the Food and Drug Administration and in line with 
the Helsinki Declaration. Sera from CRC patients were 
procured by the Midwestern and Eastern divisions of 
the Cooperative Human Tissue Network (CHTN) of 
the NCI. All sera were drawn from patients at the time 
of surgery 
 
Random peptide phage display libraries 
 
The mixture of 5-mer, 6-mer, 7-mer, 8-mer, 9-
mer, and 10-mer phage display peptide libraries were 
kindly provided by Drs. Renata Pasqualini and Wadih 
Arap. The libraries were constructed as described 
[8,10]. 
 
Isolation of phage binding antibodies from colon 
cancer patient sera 
 
We used a mixture of several libraries for the 
affinity selection of IgG and IgM immunoglobulins 
from cancer patient sera. In order to select peptides 
specific to antibodies from each serum, we developed a 
four-round procedure of phage panning. Each round of 
the protocol consisted of an initial step of 
preadsorption of the phage libraries on normal 
immunoglobulins, followed by affinity selection of the 
antibodies present in the patient serum and 
amplification of the phage particles eluted from the 
antibodies in bacteria, as described [10]. IgG or IgM 
antibodies from a CRC patient were immobilized on 
protein G (Gibco BRL) or anti-human IgM (Sigma) 
agarose, respectively. The immobilized antibodies were 
then washed in PBS and pre-blocked with 3% bovine 
serum albumin (BSA) in PBS for 30 min. 50 μl of 
colon cancer patient serum was incubated with 50 μl of 
BSA-pre-blocked protein G agarose beads for 30 min. 
In the control experiment, 50 μl of serum from a 
healthy individual was used. Likewise, 200 μl of 
pooled human sera from 24 healthy individuals were 
incubated with 200 μl of BSA-pre-blocked protein G 
agarose beads for 30 min, which were used to 
preadsorb the phage libraries on normal IgG. After 
incubation, the beads were washed in PBS four times. 
We resuspended 10[11] colony forming units (cfu) of 
phage in 200 μl of 3% BSA / 0.05% Tween 20 / PBS 
solution. The suspensions were incubated with 
immobilized IgG antibodies from the pool of healthy 
donor sera for 2h at 4° C. The phages unbound to 
normal IgG antibodies were split into equal volumes. 
One volume was transferred to protein G agarose beads 
with immobilized IgG antibodies from the serum of a  
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CRC patient, and the other volume was transferred to 
the same amount of protein G agarose beads with 
immobilized IgG antibodies from control healthy 
individuals. These phages were incubated for 2h at 4° 
C. The unbound phage was removed by 10 washes 
with 3% BSA/0.05% Tween 20/PBS buffer solution. 
The bound phages were eluted with 100 μl of 0.1M 
glycine buffer, pH 2.2, containing 1 mg/ml BSA and 
0.1 mg/ml of phenol red indicator. The eluted phage 
solution was neutralized by the addition of 1/10 
volume of 1M Tris buffer, pH 9. The neutralized phage 
was incubated with 1 ml of starved, competent E. coli 
K91kan (OD600=1-2) for 20 min at room temperature 
without shaking, followed by the addition of 10 ml of 
LB medium containing 0.2 μg/ml of tetracycline. After 
incubation at room temperature for 20min, 10 to 100-μl 
aliquots from each sample were spread on agar plates 
containing tetracycline at 40 μg/ml. The colonies were 
counted after 12 h. The remaining infected bacteria 
were grown overnight at 37° C in the presence of 40 
μg/ml tetracycline. The amplified phage were purified 
from the bacterial supernatant, quantified and subjected 
to the next round of selection. The amount of IgG or 
IgM immunoglobulins from healthy individuals used 
for preadsorption in each round of selection was 
fourfold higher than that from cancer patients. The 
binding results were quantified as the number of cfu 
produced by bacteria infected with the phage bound to 
normal and cancer patient sera antibodies. The 
biopanning procedure was considered successful when 
the number of cfu obtained after the fourth round of 
selection was at least twofold higher than those binding 
to control antibodies from healthy individuals. 
 
Sequencing of phage DNA inserts 
 
The colonies derived from the patient antibodies 
were grown overnight and the phage was purified by 
double precipitation with polyethylene-glycol. Phage 
DNAs were purified using Strataclean Resin 
(Stratagene) and sequenced with the primer  
5’-CCCTCATAGTTAAGCGTAACG-3’.  Sequencing 
was performed using the D-Rhodamine ABI prism 
automatic sequencing system (Perkin Elmer), as 
described in the manufacturer’s protocol. 
 
Expression of Peptides 
 
PCR amplifications of the peptide-encoding 
DNA inserts were performed with phage ssDNA and 
the primers 5’-AGGCTCGAGGATCCTCGGCCGACGGGGCT-
3’ (sense) and 5’-AGGTCTAGAATTCGCCCCAGCGGCCCC-3’ 
(antisense). The template was purified with phage with 
Strataclean resin (Stratagene). The PCR conditions 
included 35 cycles consisting of 1 minute at 95° C for 
denaturation, 1 minute at 53° C for annealing, and 1 
minute at 72° C for extension. The PCR products were 
ethanol-precipitated in the presence of glycogen (1 μl 
of a 20 mg/ml stock solution; Boehringer-Mannheim) 
and then digested with BamHI and EcoRI. The 
fragments were then ligated into the same restriction 
sites of the pGEX2TK vector (Promega). Bl-21 E. Coli 
cells were transformed with the constructs, and the 
fusion proteins were purified using gluthatione coupled 
beads following the manufacturer's protocol (Sigma). 
 
ELISA 
 
10  μg/ml solution of purified GST fusion 
proteins in 0.1M NaHCO3 was used to coat multi-well 
plates (50 μl per well). After washing with 0.05% 
Tween 20 / PBS (washing buffer) and blocking with 
3% BSA /0.05% Tween 20 / PBS (blocking buffer), the 
plates were incubated overnight at 4° C with cancer 
patients' and healthy individuals' sera diluted 1/200 in 
blocking buffer. The plates were then washed and 
incubated for 2h at 4° C with anti-human alkaline 
phosphatase-conjugated antibodies (GIBCO) diluted in 
blocking buffer. The plates were then washed and 
developed using p-NPP (SIGMA) as a substrate. 
 
Protein database search 
 
Homology searches with the peptide sequences 
isolated through library panning on IgG and IgM 
antibodies were performed using the BLAST module 
available on-line from NCBI (URL: 
http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The searches 
were performed against the refseq_protein database. 
The parameters of the BLAST module were adjusted 
for an optimal short motif homology search, and the 
searches were limited to human sequences. 
 
RT-PCR 
 
A multiplex RT-PCR assay was performed 
using a Clontech RT-PCR kit. 2 μg of DNAase-treated 
RNA from normal and colon tumor tissues were used 
with random hexamers to synthesize the first strand. 
Control G3PDH and FUT6 gene fragments were 
amplified in a single PCR reaction. The primers used 
for amplification of the FUT6 cDNA fragment were:  
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5’- ATGGATCCCCTGGGCCCGGCCA-3’ (sense) 
and 5’-CCGTAGGGCGTGAAGATGT-3’ (antisense). 
The primers used for amplification of a 983-bp 
fragment of the control G3PDH gene were supplied 
with the RT-PCR kit. PCR conditions were 35 rounds 
each consisting of 1 min at 95° C, 1 min at 58° C, and 
4 min at 72° C; the PCR reactions were concluded with 
a final extention step of 10 min at 72° C. PCR products 
were visualized by electrophoresis on a 1% agarose 
gel. 
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